RxDoctor Payments Data

Jordan Henderson, DO

Hematology & Oncology · Myrtle Beach, SCNPI 1013200328

Payments from drug & device makers

$6,475in general payments, 2019–2025

Across 303 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$465
  • Bristol Myers Squibb$419
  • Jazz Pharmaceuticals Inc.$341
  • Incyte Corporation$310
  • AstraZeneca$310
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$5,53686%
  • Education$4567%
  • Other$4827%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,475 in reported general payments places this provider in the 45th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$9,944,251
Medicare patients
1,085
Services billed
383,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide42$780,135
Lenalidomide46$629,197
PomalystPomalidomide20$442,362
ImbruvicaIbrutinib19$385,780
XtandiEnzalutamide17$235,280
AlecensaAlectinib Hcl12$226,913
TabrectaCapmatinib Hydrochloride14$171,295
Abiraterone Acetate13$86,379
VenclextaVenetoclax12$48,089
XareltoRivaroxaban17$26,199
EliquisApixaban27$17,647
CholestyramineCholestyramine (With Sugar)17$1,999
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$1,773
Hydroxyurea38$1,360
Dexamethasone52$1,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$419$780,13542 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$465$442,36220 claims
Astellas Pharma US IncXtandi$18$235,28017 claims
Genentech USA, Inc.Alecensa$264$226,91312 claims
NovartisTabrecta$1,027$171,29514 claims
AbbVieVenclexta$89$48,08912 claims
Johnson & JohnsonXarelto$165$26,19917 claims
PfizerEliquis$42$17,64727 claims
Lilly USA, LLCOlanzapine$83$8421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 166 hematology & oncology providers in South Carolina.

Other hematology & oncology in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →